World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
93
Citations
41075
World Ranking
953
National Ranking
525

Medicine

D-Index
94
Citations
41876
World Ranking
10318
National Ranking
5306

Overview

Joan T. Merrill is affiliated with the Oklahoma Medical Research Foundation in the United States. Their research primarily focuses on the field of Medicine, with particular attention to Rheumatology, Immunology, Radiology, Nuclear Medicine and Imaging, Oncology, and Pathology and Forensic Medicine.

The scientist's work explores topics including:

  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Cytokine Signaling Pathways and Interactions
  • T-cell and B-cell Immunology
  • Atherosclerosis and Cardiovascular Diseases
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment

Joan T. Merrill has published extensively, contributing to journals frequently associated with their research area. The most common publication venues include:

  • Annals of the Rheumatic Diseases
  • UNC Libraries
  • The Journal of Rheumatology
  • Arthritis & Rheumatology
  • Lupus Science & Medicine

Frequent co-authors collaborating with Joan T. Merrill are:

  • Kenneth Kalunian
  • Cynthia Aranow
  • David Isenberg
  • Susan Manzi
  • Daniel J. Wallace

Notable recent papers by Joan T. Merrill include:

  • "Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications," 2020, Nature Reviews Rheumatology
  • "Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial," 2022, Arthritis & Rheumatology
  • "Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials," 2022, Annals of the Rheumatic Diseases
  • "Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort," 2021, Lara D. Veeken
  • "Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial," 2023, Annals of the Rheumatic Diseases

Best Publications

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

    Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon

  • Human polymorphism at microRNAs and microRNA target sites.

    Liuqing Yang;Chunru Lin;Chunyu Jin;Joy C. Yang

  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

    Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera

  • American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

    Bevra H. Hahn;Maureen A. McMahon;Alan Wilkinson;W. Dean Wallace

  • Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial

    Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan

  • Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.

    John B. Harley;John B. Harley;John B. Harley;Marta E. Alarcón-Riquelme;Lindsey A. Criswell;Chaim O. Jacob

  • Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

    Ellen M. Ginzler;Mary Anne Dooley;Cynthia Aranow;Mimi Y. Kim

  • Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

    Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth

  • The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial

    Jill P. Buyon;Michelle A. Petri;Mimi Y. Kim;Kenneth C. Kalunian

  • The frequency and outcome of lupus nephritis: results from an international inception cohort study

    John G. Hanly;Aidan G. O'Keeffe;Li Su;Murray B. Urowitz

  • A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

    Daniel J. Wallace;William Stohl;Richard A. Furie;Jeffrey R. Lisse

  • Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study

    Jill P. Buyon;Mimi Y. Kim;Marta M. Guerra;Carl A. Laskin

  • Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

    Munther Khamashta;Joan T Merrill;Victoria P Werth;Victoria P Werth;Richard Furie

  • Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

    Susan Manzi;Jorge Sánchez-Guerrero;Joan T Merrill;Richard Furie

  • Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

    Kenneth C. Kalunian;John C. Davis;Joan T. Merrill;Mark C. Totoritis

  • Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

    Richard A. Furie;Michelle A. Petri;Daniel J. Wallace;Ellen M. Ginzler

  • Prediction of Adverse Pregnancy Outcome by the Presence of Lupus Anticoagulant, but Not Anticardiolipin Antibody, in Patients With Antiphospholipid Antibodies

    Michael D. Lockshin;Mimi Kim;Carl A. Laskin;Marta Guerra

  • Transancestral mapping and genetic load in systemic lupus erythematosus

    Carl D. Langefeld;Hannah C. Ainsworth;Deborah S. Cunninghame Graham;Jennifer A. Kelly

  • A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

    Kenneth C Kalunian;Joan T Merrill;Romeo Maciuca;Jacqueline M McBride

  • A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus.

    Swapan K. Nath;Shizhong Han;Xana Kim-Howard;Jennifer A. Kelly

  • Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

    Richard Furie;William Stohl;Ellen M Ginzler;Michael Becker

  • The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial

    J. T. Merrill;R. Burgos-Vargas;R. Westhovens;A. Chalmers

Frequent Co-Authors

Judith A. James
Judith A. James Oklahoma Medical Research Foundation
Michelle Petri
Michelle Petri Johns Hopkins University School of Medicine
Graciela S. Alarcón
Graciela S. Alarcón University of Alabama at Birmingham
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Daniel J. Wallace
Daniel J. Wallace Cedars-Sinai Medical Center
Kenneth C. Kalunian
Kenneth C. Kalunian University of California, San Diego
John B. Harley
John B. Harley United States Department of Veterans Affairs
Caroline Gordon
Caroline Gordon University of Birmingham
Sang-Cheol Bae
Sang-Cheol Bae Hanyang University
Cynthia Aranow
Cynthia Aranow Feinstein Institute for Medical Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Many professionals in immunology collaborate closely with nursing and healthcare practitioners, making interdisciplinary understanding valuable. Accelerated programs provide a fast-track to entering the healthcare field, especially for those transitioning from other disciplines.

Online options like accelerated np programs are ideal for individuals aiming to become nurse practitioners swiftly. These programs combine rigorous training with flexibility, accommodating working students.

If you’re coming from a non-nursing background, consider 12-month accelerated nursing programs online for non nurses, which offer focused training to jumpstart your nursing career in just one year. Such programs emphasize foundational skills crucial for clinical roles linked to immunological health.

Additionally, those seeking quicker entry points may explore 12-month accelerated nursing programs that balance accessibility and efficiency. For entry-level positions, lpn programs easy to get into provide practical education and licensing pathways, serving as a foundational step toward advanced immunology-related careers.

Best Scientists Citing Joan T. Merrill

Trending Scientists